CTSH

Cognizant Technology Solutions

$58.06

+3.11%
Nov 20, 2026
Bobby Quantitative Model
Cognizant Technology Solutions is a multinational IT services and consulting firm providing digital engineering, cloud migration, application development and maintenance, business process outsourcing, and increasingly AI-led transformation services to enterprise clients concentrated in financial services, healthcare, communications/media/technology, and products and resources. Unlike pure offshore cost-arbitrage vendors, Cognizant positions itself as a consultative, industry-domain-led partner with a roughly 360,000-person global delivery model anchored in India but headquartered in the US, placing it in the large-cap IT services cohort alongside Accenture, Infosys, TCS and Wipro. The current investor debate centers on whether generative AI is a net tailwind (new transformation budgets, data modernization) or a deflationary threat to the traditional time-and-materials model, compounded by soft discretionary IT spending, healthcare client budget scrutiny, and margin pressure from the company's own AI and platform investments. Recent quarterly results showing low-single-digit revenue growth (approximately 4.6% year-over-year) alongside a depressed share price and a heavily discounted forward multiple have turned the narrative into a value-versus-secular-decline argument, with bulls pointing to a fortress balance sheet, high free cash flow conversion and a 1.5% dividend yield, and bears citing persistent growth underperformance versus peers and a stock that has badly lagged the market over the past year.

People also watch

IBM

IBM

IBM

Analysis
Accenture

Accenture

ACN

Analysis
Fiserv

Fiserv

FISV

Analysis
Broadridge Financial Solutions

Broadridge Financial Solutions

BR

Analysis
Fidelity National Information Services

Fidelity National Information Services

FIS

Analysis

BobbyInvestment Opinion: Should I buy CTSH Today?

Rating: Hold, with a constructive bias toward accumulating on stabilization. The core thesis is that Cognizant is a cheap, cash-generative, fortress-balance-sheet IT services business whose 8.97x forward PE and 5.8% FCF yield already discount a great deal of AI-era pessimism, but whose 4.6% revenue growth and 17.4% one-month decline mean there is no catalyst yet to force a re-rating — consistent with the 12 Buy / 17 Hold / 0 Sell consensus (mean rating 2.28) and the $69.42 average target implying 23.3% upside.

The supporting evidence is genuinely two-sided. On valuation, EV/EBITDA of 9.86x, PS of 1.92x and EV/Sales of 1.21x sit at or below typical large-cap IT services levels where leaders like Accenture command low-to-mid-teens EV/EBITDA, and the PS multiple has collapsed from 7.5x-9.7x in 2021-2022 to 1.92x today. On profitability, Q3 2026 net margin of 11.07% recovered from the tax-distorted 5.06% a year earlier, operating margin is 15.40% and EBITDA margin 18.20%, while TTM free cash flow of $2.363 billion funds a 1.5% dividend at a 27.4% payout ratio plus $270 million of Q3 buybacks. On growth, however, revenue of $5.664 billion grew only 4.6% year-over-year and the PEG ratio of 16.42 shows the market is paying almost nothing for that growth — the discount is earned, not gifted. The 23.3% upside to the $69.42 average target is real but sits against a $47 low target only 17% below spot, a 79% wide dispersion that signals disagreement rather than conviction.

The biggest risks that could invalidate the thesis are (1) AI-driven deflation of billable hours compressing the time-and-materials model faster than new transformation work offsets it, (2) consensus 2027 EPS of $6.26 proving too optimistic versus the $1.36-$1.39 quarterly run-rate (roughly $5.50 annualized), which would remove the valuation floor, and (3) continued discretionary budget freezes at Financial Services ($1.767 billion) and Healthcare ($1.587 billion), which together are about 59% of revenue. This Hold would upgrade to Buy if the stock reclaims the $62-$66 shelf and revenue growth reaccelerates above mid-single digits, or if the forward multiple stays under 9x while FCF conversion holds above 5%; it would downgrade to Sell on a break below the $56-$58 support cluster that opens a path toward the $47 low target. Net verdict: fairly valued to modestly undervalued relative to its own history and peers, but not yet a compelling entry — cheap for a reason until growth stabilizes.

Sign up to view all

CTSH 12-Month Price Forecast

The forward view is genuinely balanced: valuation is undemanding at 8.97x forward earnings and 9.86x EV/EBITDA, cash generation is robust at a 5.8% FCF yield, and the balance sheet is pristine at 0.105 debt-to-equity, yet growth of 4.6% and a 17.4% one-month decline show the market is pricing secular risk rather than a temporary lull. The 55% base case of a grind toward the $69.42 average target is the most probable outcome, with a 25% bear tail toward the $37-$47 zone carrying more weight than the 20% bull tail toward $84 because the near-term technical structure is broken and relative strength versus SPY is -30.1% over one year. I would upgrade to bullish if revenue growth prints above 6% for two consecutive quarters or the stock reclaims the $62-$66 shelf on volume, and downgrade to bearish if consensus 2027 EPS is cut below $6.00 or the $56 support fails decisively. Confidence is medium rather than high because the AI tailwind-versus-deflation question — the single variable that determines whether 8.97x is a value trap or a generational entry — remains unresolved by the data.

Historical Price
Current Price $58.06
Average Target $66.00
High Target $84.00
Low Target $37.08

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Cognizant Technology Solutions's 12-month outlook, with a consensus price target around $69.42 and implied upside of +19.6% versus the current price.

Average Target

$69.42

30 analysts

Implied Upside

+19.6%

vs. current price

Analyst Count

30

covering this stock

Price Range

$47 - $84

Analyst target range

Buy
12 (40%)
Hold
18 (60%)
Sell
0 (0%)

Coverage is broad and institutional, with 25 analysts and a distribution of 12 Buy, 17 Hold and 0 Sell — a consensus recommendation of "buy" (mean rating 2.28 on a scale where lower is more bullish) that in practice leans cautiously neutral given the Hold majority. The average target price of $69.42 implies roughly 23.3% upside from the current $56.31, and consensus 2027 EPS of $6.26 on estimated revenue of $24.74 billion (range $24.48–$25.10 billion) suggests analysts expect modest growth and stable margins rather than a turnaround. The sentiment is best characterized as "constructive but unenthusiastic": no analyst is willing to call it a Sell at these levels, but the majority will not commit to a Buy until growth reaccelerates, and the recent rating actions — RBC Capital and Morgan Stanley maintaining Sector Perform/Equal Weight on October 30, JP Morgan and Wells Fargo reiterating Overweight on October 26, TD Cowen holding at Hold on October 13 — show a stable, unexcited consensus with no meaningful upgrades or downgrades.

The target range of $47.00 to $84.00 is extremely wide — a 79% spread from low to high — signaling genuine disagreement about the company's trajectory rather than strong conviction. The $84 high target implies roughly 49% upside and would require multiple expansion back toward historical norms plus evidence that AI-led transformation demand reaccelerates growth into the high single digits; the $47 low target implies about 17% downside and prices in continued growth stagnation, margin compression from AI investment and wage inflation, and further multiple contraction toward the low end of the historical band. The fact that the current price of $56.31 sits in the lower third of the target range, combined with the stock's 17.4% one-month decline, suggests the market is gravitating toward the bearish end of the analyst distribution — and with the average target 23% above spot but the low target only 17% below, the risk/reward is modestly favorable but far from compelling until the price action stabilizes above the $56–$58 support zone.

Drowning in data?

Find the real signal!

Bulls vs Bears: CTSH Investment Factors

The bear case currently carries stronger near-term evidence: revenue growth of just 4.6%, a 17.4% one-month decline, relative strength of -30.1% versus SPY over a year, and a broken technical structure that has given back most of the July-October rally. The bull case rests on valuation and balance-sheet strength — a 5.8% FCF yield, 0.105 debt-to-equity, forward PE under 9x, and 23.3% implied upside to the $69.42 average target — but cheapness alone has not arrested the de-rating for multiple quarters. The single most important tension is whether AI is a net tailwind (new transformation budgets, data modernization) or a deflationary force compressing the time-and-materials model; how that resolves determines whether the 8.97x forward multiple is a value trap or a generational entry point. Until growth stabilizes above mid-single digits and the price reclaims the $62-$66 shelf, the weight of evidence favors caution over conviction.

Bullish

  • Deep discount to sector multiples: CTSH trades at an EV/EBITDA of 9.86x, PS of 1.92x and forward PE of just 8.97x, all at or below typical large-cap IT services levels where peers like Accenture command EV/EBITDA in the low-to-mid teens. The PS ratio has collapsed from 7.5x-9.7x in 2021-2022 to 1.92x today, placing the stock near the bottom of its own historical valuation band.
  • Fortress balance sheet and cash generation: Debt-to-equity is only 0.105 and the current ratio is 2.34, while TTM free cash flow of $2.363 billion against a $40.5 billion market cap implies a 5.8% FCF yield. That cash flow comfortably covers the 1.5% dividend (27.4% payout ratio) and funded $270 million of Q3 buybacks plus $149 million of dividends.
  • Analyst targets imply 23% upside: The average target price of $69.42 implies roughly 23.3% upside from $56.31, with 12 Buy ratings and zero Sells across 25 analysts. The $84 high target would represent about 49% upside if AI-led transformation demand reaccelerates growth into the high single digits.
  • Margins recovering from trough: Q3 2026 net margin of 11.07% recovered sharply from the tax-distorted 5.06% in Q3 2025, and gross margin of 33.77% is up from the 29.63% trough in Q1 2026. Operating margin of 15.40% and EBITDA margin of 18.20% confirm a reliably profitable business despite the growth ceiling.

Bearish

  • Growth stuck in low single digits: Q3 2026 revenue of $5.664 billion grew only 4.6% year-over-year, and the sequential cadence of $5.413B to $5.481B to $5.664B shows steady but non-accelerating expansion. The PEG ratio of 16.42 is extraordinarily high precisely because the growth denominator is near zero, making the low multiple a rational discount rather than a mispricing.
  • Severe and accelerating underperformance: The stock is down 22.1% over the trailing year and 30.7% year-to-date, with relative strength versus SPY at -30.1% over one year and -35.7% YTD. The one-month decline of 17.4% (versus SPY's -6.92%) shows the underperformance is accelerating, not stabilizing.
  • Damaged technical structure: At $56.31 the stock sits at only 39.6% of its 52-week range of $37.08-$87.03, and the -55.33% max drawdown underscores how violent the de-rating has been. The failure to hold the October breakout above $70 and the 15.4% slide from $66.54 on November 5 to $56.31 on November 19 argue the July-October rally was a bear-market bounce.
  • Wide analyst dispersion signals uncertainty: The target range of $47 to $84 is a 79% spread, signaling genuine disagreement about the company's trajectory rather than conviction. With 17 of 25 analysts at Hold and a mean rating of 2.28, the consensus is constructive but unenthusiastic, and no meaningful upgrades have appeared in recent rating actions.

CTSH Technical Analysis

Cognizant is in a structurally damaged downtrend that has only partially repaired: the stock is down 22.1% over the trailing year and 30.7% year-to-date, and at $56.31 it sits at roughly 39.6% of its 52-week range of $37.08 to $87.03 — closer to the floor than the ceiling, which frames the current setup as a recovery attempt within a larger bear phase rather than a clean uptrend. The 52-week high of $87.03 is 54.6% above the current price, while the 52-week low of $37.08 is only 34.1% below it, and the maximum drawdown of -55.33% underscores how violent the de-rating has been; positioning this far below the highs means the stock is neither an extended momentum name nor a clean falling knife, but a damaged chart that has already absorbed significant selling. The most important structural feature is the June 2026 capitulation, when the stock collapsed from $51.05 on June 16 to $38.74 by June 29 — a roughly 24% two-week drawdown — followed by a powerful V-shaped recovery to $73.72 on October 22, a 90% rebound off the low that has since given back a large chunk of those gains.

Short-term momentum has turned decisively negative and is diverging sharply from the six-month trend: the stock is down 17.4% over the past month and 9.0% over three months, even though it remains up 6.7% over six months, meaning the entire six-month gain was earned in the July–October rally and is now being eroded. The relative strength figures confirm the underperformance is accelerating — -10.49% versus SPY over one month and -2.48% over three months, against a positive +10.74% relative strength over six months — a classic pattern of a counter-trend rally exhausting itself. The last eight sessions tell the story of the reversal: from $66.54 on November 5 to $56.31 on November 19, a 15.4% slide including a -2.83% down day on the most recent session on elevated volume of 6.57 million shares, with the stock closing near the day's low. This one-month weakness against a still-positive six-month base signals distribution and mean reversion rather than a healthy consolidation, and the failure to hold the October breakout above $70 argues the July–October advance was a bear-market rally, not a new trend.

Key technical levels are now clearly defined: immediate support sits at the November 17–19 cluster around $56–$58, with the more meaningful floor at the October 29 swing low of $62.52 already broken and the deeper structural support at the June low of $38.74 and the 52-week low of $37.08. Resistance is layered at $62–$66 (the broken November shelf), then $73.72 (the October 22 rally peak), with the 52-week high of $87.03 as the long-term ceiling; a reclaim of $66 would neutralize the near-term downtrend, while a break below $56 opens a path toward the $50s and ultimately retests the summer lows. Volatility context matters for sizing: the beta of 0.827 implies the stock should be roughly 17% less volatile than SPY, yet the -55.33% max drawdown and the 24% two-week June collapse show idiosyncratic, event-driven risk that beta understates — the short ratio of 3.27 (about 3.3 days of average volume to cover) adds squeeze potential on any positive catalyst, but the current tape suggests sellers remain in control.

Beta

0.83

0.83x market volatility

Max Drawdown

-55.3%

Largest decline past year

52-Week Range

$37-$87

Price range past year

Annual Return

-19.8%

Cumulative gain past year

PeriodCTSH ReturnS&P 500
1m-16.5%-9.7%
3m-6.2%-9.9%
6m+10.1%-7.5%
1y-19.8%+4.7%
ytd-28.6%+1.2%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

CTSH Fundamental Analysis

Revenue is growing but at a modest, decelerating pace: Q3 2026 revenue of $5.664 billion rose 4.6% year-over-year versus $5.415 billion in Q3 2025, and the sequential cadence — $5.413 billion in Q1, $5.481 billion in Q2, $5.664 billion in Q3 — shows steady but low-single-digit expansion rather than acceleration. Segment mix reveals where the growth burden sits: Financial Services is the largest at $1.767 billion, followed by Healthcare at $1.587 billion, Products and Resources at $1.371 billion, and Communication, Media and Technology at $939 million, meaning the company is heavily levered to financial services and healthcare budgets that have been under discretionary pressure. The trajectory implies a business grinding out mid-single-digit growth in a market that rewards AI-driven acceleration, which is precisely why the stock has de-rated — the investment case now rests on stabilization and margin defense rather than top-line reacceleration.

Profitability remains solid and, importantly, is improving: Q3 2026 net income of $627 million on $5.664 billion of revenue produced a 11.07% net margin, up from the depressed 5.06% net margin in Q3 2025 (which was distorted by a $613 million tax charge against $887 million pretax income), and gross margin of 33.77% was essentially flat versus 33.87% a year earlier but up from the 29.63% trough in Q1 2026. Operating income of $872 million equates to a 15.40% operating margin, and EBITDA of $1.031 billion represents an 18.20% EBITDA margin — healthy for IT services, though below the 19.0%+ EBITDA margins posted in mid-2025 quarters, suggesting mild compression from AI investment and wage costs. The key takeaway is that Cognizant is a reliably profitable, cash-generative business with double-digit net margins and mid-teens operating margins; the problem is not profitability but the growth ceiling, and margin expansion from here will have to come from utilization, automation and pyramid mix rather than revenue leverage.

Financial health is a genuine strength: debt-to-equity of just 0.105, a current ratio of 2.34, and trailing twelve-month free cash flow of $2.363 billion against a $40.5 billion market cap imply an FCF yield of roughly 5.8%, comfortably covering the 1.5% dividend yield (payout ratio 27.4%). Quarterly free cash flow has been lumpy — $925 million in Q3 2026, $459 million in Q2, $198 million in Q1 — but operating cash flow of $1.004 billion in Q3 and $2.363 billion TTM confirms the business funds itself internally while still returning capital via $270 million of Q3 buybacks and $149 million of dividends. ROE of 14.85% and ROA of 10.78% are respectable but not exceptional for the sector, and the low leverage means there is ample balance-sheet capacity for tuck-in acquisitions (Q1 and Q2 2026 saw $730 million and $604 million of acquisition outlays) — the risk is capital allocation into deals that dilute returns rather than any liquidity or solvency concern.

Quarterly Revenue

$5.7B

2026-09

Revenue YoY Growth

+4.6%

YoY Comparison

Gross Margin

33.8%

Latest Quarter

Free Cash Flow

$2.4B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Communication, Media and Technology
Financial Services
Healthcare Segment
Products and Resources

Open an Account, get $2 TSLA now!

Valuation Analysis: Is CTSH Overvalued?

Because Cognizant is solidly profitable (Q3 2026 net income of $627 million; TTM EPS positive), the PE ratio is the appropriate primary metric, and the picture is one of stark cheapness: the trailing PE is 18.16x while the forward PE is just 8.97x, an enormous 51% compression that implies the market expects earnings to roughly double — or, more plausibly, that the trailing figure is distorted and the forward estimate of $6.26 in EPS (versus a trailing figure implying roughly $3.10) reflects a normalization the market is discounting skeptically. The gap between trailing and forward multiples is unusually wide and itself a red flag: either consensus EPS of $6.26 is too optimistic relative to the quarterly run-rate of $1.36–$1.39 (which annualizes to about $5.50), or the trailing PE is inflated by one-off items — in either case, the market is pricing in substantial doubt about earnings durability.

On peer-relative grounds the stock screens cheap across nearly every metric: PS of 1.92x, EV/Sales of 1.21x, EV/EBITDA of 9.86x, price-to-book of 2.70x, and price-to-cash-flow of 14.05x are all at or below typical large-cap IT services levels, where EV/EBITDA in the low-to-mid teens is common for growth leaders like Accenture. The PEG ratio of 16.42 is the tell — it is extraordinarily high because the growth denominator is near zero, meaning the low multiple is not a mispricing but a rational discount for a business growing revenue at 4.6% with limited margin expansion. In other words, Cognizant trades at a discount to the sector because it deserves one on growth; the question for investors is whether the discount (EV/EBITDA of 9.86x versus a sector that often commands 12–15x) over-punishes a 15%+ operating-margin, 5.8% FCF-yield business.

Historical context reinforces the de-rating story: the stock's own PE has compressed from roughly 16–17x in 2023–2024 (e.g., 16.86x at Q4 2023, 17.48x at Q4 2024) to 18.16x trailing today but with a forward multiple of under 9x, and its PS ratio has fallen from the 7.5x–9.7x range in 2021–2022 to 1.92x now — a collapse of more than 70% in the sales multiple that reflects both the growth slowdown and the market's reassessment of IT services economics in the AI era. The stock is therefore near the bottom of its own historical valuation band on sales and cash-flow metrics, which historically has marked value opportunities — but the persistence of the compression across multiple quarters (PS fell from 7.49x in Q4 2025 to 4.56x in Q3 2026 on the historical series) suggests fundamental deterioration is being priced, not just sentiment, and a re-rating requires evidence of growth stabilization that has not yet appeared.

PE

18.2x

Latest Quarter

vs. Historical

High-End

5-Year PE Range 10x~21x

vs. Industry Avg

19.1x

Industry PE ~19.1x*

EV/EBITDA

9.9x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on the growth ceiling rather than solvency: revenue grew only 4.6% year-over-year to $5.664 billion in Q3 2026, and the PEG ratio of 16.42 shows the market is paying almost nothing for growth that is barely above inflation. EBITDA margin of 18.20% has compressed from the 19.0%+ levels posted in mid-2025 quarters, and gross margin of 33.77% is only marginally above the 29.63% Q1 2026 trough, meaning AI investment and wage inflation are eroding the margin buffer. Revenue concentration adds vulnerability — Financial Services ($1.767 billion) and Healthcare ($1.587 billion) together represent roughly 59% of the quarter's revenue, both segments facing discretionary budget scrutiny. The trailing-to-forward PE gap (18.16x versus 8.97x) is itself a red flag: consensus EPS of $6.26 versus a quarterly run-rate of $1.36-$1.39 (annualizing to about $5.50) means either estimates are too optimistic or trailing earnings are distorted, and any downward revision would remove the valuation support underpinning the bull case. Market and competitive risks are dominated by multiple compression and AI disruption. The stock's PS ratio has fallen from 7.5x-9.7x in 2021-2022 to 1.92x today, a collapse of more than 70%, and the persistence of that compression across quarters (PS fell from 7.49x in Q4 2025 to 4.56x in Q3 2026) suggests fundamental deterioration is being priced rather than mere sentiment. With a beta of 0.827 the stock should be about 17% less volatile than SPY, yet it has underperformed SPY by 30.1% over one year and 35.7% YTD, showing idiosyncratic, event-driven risk that beta understates. Competitive pressure from Accenture, Infosys, TCS and Wipro — plus the possibility that generative AI deflates billable hours in the time-and-materials model — threatens both pricing power and volume, while sector rotation away from IT services compounds the de-rating. The worst-case scenario is a chain in which AI-driven deflation compresses billable hours, healthcare and financial services budgets stay frozen, consensus EPS of $6.26 is revised toward the $5.50 run-rate, and the forward multiple fails to expand — pushing the stock back toward the June low of $38.74 and the 52-week low of $37.08. From the current $56.31, that represents roughly -31% to -34% downside, consistent with the analyst low target of $47 (-17%) being breached in a genuine growth scare. The -55.33% max drawdown and the 24% two-week collapse in June 2026 (from $51.05 to $38.74) demonstrate how quickly such a scenario can unfold, and a break below the $56-$58 support cluster would open a direct path toward the $50s and ultimately a retest of the summer lows.

FAQ

Ranked by severity: first, growth stagnation — revenue grew only 4.6% year-over-year to $5.664 billion in Q3 2026 and the PEG of 16.42 means any further deceleration removes the valuation floor, especially if consensus 2027 EPS of $6.26 is revised toward the $5.50 run-rate. Second, AI-driven disruption of the time-and-materials model, which threatens both pricing power and volume, with EBITDA margin already at 18.20% versus 19.0%+ in mid-2025 quarters. Third, revenue concentration — Financial Services ($1.767 billion) and Healthcare ($1.587 billion) are roughly 59% of revenue and both face discretionary budget scrutiny. Fourth, market and technical risk: despite a beta of 0.827, the stock has underperformed SPY by 30.1% over one year and 35.7% YTD, and a break below $56-$58 opens a path toward the $47 low target and the $37.08 52-week low, roughly -34% downside.

The three-scenario framework assigns a 55% probability to the base case of $62-$70, in which Cognizant delivers roughly $6.26 in 2027 EPS, holds 15-16% operating margins, and the multiple stays range-bound between 9x and 11x forward, anchoring near the $69.42 average target. The 25% bear case targets $37.08-$47, driven by AI deflation, frozen healthcare and financial services budgets, and EPS revised toward the $5.50 run-rate, retesting the June low of $38.74. The 20% bull case targets $78-$84, requiring revenue growth to reaccelerate into the high single digits and the forward multiple to expand from 8.97x toward historical norms of 12-14x, landing near the $84 high target. The base case is most likely, and its key assumption is that growth holds in the 4-6% band with no further margin compression and no downward EPS revision.

On nearly every metric CTSH screens cheap: trailing PE of 18.16x collapses to a forward PE of just 8.97x, alongside PS of 1.92x, EV/Sales of 1.21x, EV/EBITDA of 9.86x, price-to-book of 2.70x and price-to-cash-flow of 14.05x — all at or below typical large-cap IT services levels where leaders like Accenture command low-to-mid-teens EV/EBITDA. The stock's own PS ratio has fallen from the 7.5x-9.7x range in 2021-2022 to 1.92x today, a collapse of more than 70%, placing it near the bottom of its historical band. However, the PEG ratio of 16.42 is the tell: the multiple is low because growth is near zero, so the market is paying a rational discount rather than mispricing the stock. The unusually wide trailing-to-forward PE gap also implies skepticism about the $6.26 consensus EPS versus the roughly $5.50 annualized run-rate. Net verdict: modestly undervalued relative to its own history and peers, but cheap for a reason until growth stabilizes.

From a risk/reward standpoint the setup is modestly favorable but not compelling: the $69.42 average analyst target implies about 23.3% upside from $56.31, while the $47 low target implies roughly 17% downside, and the 12 Buy / 17 Hold / 0 Sell distribution means no analyst sees a Sell but most will not commit to a Buy. The valuation support is real — 8.97x forward PE, 9.86x EV/EBITDA, a 5.8% FCF yield and 0.105 debt-to-equity — but the PEG of 16.42 and 4.6% revenue growth show the market is discounting secular risk rather than a temporary lull. The biggest downside risk is a break below the $56-$58 support cluster that opens a retest of the $37.08 52-week low, roughly -34%. It is a reasonable buy for patient value investors with a 12-24 month horizon who can tolerate volatility and want the 1.5% dividend, but momentum-oriented investors should wait for a reclaim of the $62-$66 shelf or two consecutive quarters of revenue growth above 6%.

CTSH is better suited to a long-term hold than a short-term trade. It is a mature, low-growth business (4.6% revenue growth) with a beta of 0.827 that understates its idiosyncratic risk — the -55.33% max drawdown and the 24% two-week June collapse from $51.05 to $38.74 show event-driven volatility that punishes short-term positioning. The 1.5% dividend at a 27.4% payout ratio and $2.363 billion of TTM free cash flow provide a return floor for patient holders, while the 8.97x forward multiple means the re-rating case depends on multi-quarter evidence of growth stabilization rather than a single catalyst. Earnings visibility is moderate — consensus 2027 EPS of $6.26 versus a $5.50 run-rate is unresolved — so a minimum holding period of 12-24 months is appropriate to capture the base-case mean reversion toward $69.42. Short-term traders could work the $56-$58 support and $62-$66 resistance range, but the risk/reward for that is thin given the 79% analyst target dispersion.